Australia markets close in 6 hours 4 minutes

Biohaven Ltd. (BHVN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
39.61+1.28 (+3.34%)
At close: 04:00PM EDT
40.42 +0.81 (+2.04%)
After hours: 07:59PM EDT

Biohaven Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410

Full-time employees239

Key executives

NameTitlePayExercisedYear born
Dr. Vladimir Coric M.D.Chairman & CEO1.96MN/A1971
Mr. Matthew ButenChief Financial Officer1.05MN/A1961
Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer883.03kN/A1962
Ms. Kimberly GentileSenior Vice President of Clinical Operations858.65kN/A1966
Ms. Deb YoungDirector of Regulatory Affairs & OperationsN/AN/AN/A
Mr. George C. ClarkVP & Chief Accounting OfficerN/AN/A1984
Ms. Jennifer PorcelliVice President of Investor RelationsN/AN/AN/A
Mr. Warren Volles J.D.General Counsel & Chief Legal OfficerN/AN/AN/A
Mr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerN/AN/AN/A
Mr. John TiltonChief Commercial Officer of Rare DiseasesN/AN/A1968
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Corporate governance

Biohaven Ltd.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.